Clinical trials related to food allergy have several drawbacks. Access is extremely limited, and many participants are excluded due to their age, the severity of their allergies, other conditions, or other reasons. Trial parameters often require clinicians to establish an “eliciting dose” by putting the participants selected into potentially life-threatening anaphylaxis before treatment. Many of the participants who continue with a trial receive a placebo instead of treatment. Those participants who are treated receive the trial’s preset, standardized protocol, regardless of their individual needs, preferences, or resulting side-effects. Trial goals are study-based, not patient-based, and patients receive no follow-up care or long-term monitoring. For these reasons, many families decide against participating in clinical trials.